U
Upstream Bio
Focuses on developing an antibody therapy for the treatment of severe asthma
About Upstream Bio
Upstream Bio is a biotechnology startup focused on developing innovative therapies to treat inflammatory and allergic diseases. The company operates in the biopharmaceutical market, targeting conditions that cause significant discomfort and health issues for patients. Their primary clients are healthcare providers and patients who suffer from chronic inflammatory conditions such as asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
Read full description
The company's lead product, verekitug, is a monoclonal antibody designed to inhibit the TSLP receptor, a key player in the inflammatory process. Verekitug has successfully completed Phase 1b clinical trials for asthma and is currently in Phase 2 trials for both asthma and CRSwNP. Monoclonal antibodies are lab-made proteins that can bind to specific targets in the body, and in this case, verekitug aims to block the receptor that triggers inflammation.
Upstream Bio's business model revolves around research and development (R&D) of these specialized therapies. They invest heavily in clinical trials to ensure the safety and efficacy of their products. Once a therapy proves successful in clinical trials, the company can either bring it to market themselves or partner with larger pharmaceutical companies for distribution and commercialization. This approach allows them to generate revenue through product sales, licensing agreements, and potential milestone payments from partners.
The company is deeply committed to patient-centric values, ensuring that their work directly improves the quality of life for those suffering from inflammatory diseases. By focusing on the root causes of inflammation, Upstream Bio aims to provide long-term relief and better health outcomes for patients.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Waltham, United States
- Employees
- 82
- Open positions
- 4
- Dealroom signal
- 91.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Respiratory, Inflammatory Diseases, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Oct 2024 | $293M | $1.1B | Undisclosed | ↗ |
| SERIES BOther financing | Jun 2023 | $200M | $800M | Omega Funds · Altshuler Shaham · Bain Capital Life Sciences · Venrock Healthcare Capital Partners | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Upstream Bio is 3.5K monthly website visits, down 37.5% over the last three months. Upstream Bio's team grew 20.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A13 investors entered at this stage
HBM Healthcare Investments
OrbiMed- MAMaruho
Omega Funds
Altshuler Shaham
Access Biotechnology
Decheng Capital
Samsara BioCapital
TCGX
Bain Capital Life Sciences- VPVenrock Healthcare Capital Partners
Enavate Sciences
Wellington Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Upstream Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Upstream Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.